FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 352:1133-1135 March 17, 2005 Number 11 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Solomon, S. D. Related Article by Nussmeier, N. A. Related Article by Bresalier, R. S. PubMed Citation

Approximately six years after the cyclooxygenase-2 (COX-2) inhibitors were approved for use in the United States, the results of three randomized, placebo-controlled trials provide new evidence about the cardiovascular risks of rofecoxib, celecoxib, and valdecoxib.^1,2,3 The Adenomatous Polyp Prevention on Vioxx (APPROVe) trial, a study of patients with a history of colorectal adenomas, was stopped early because rofecoxib doubled the risk of major cardiovascular events (relative risk, 1.92; 95 percent confidence interval, 1.19 to 3.11). These findings confirmed the increased risk of myocardial infarction previously seen in the Vioxx Gastrointestinal Outcomes Research (VIGOR) trial⁴ and some observational studies.⁵ The public . . . [Full Text of this Article]

Source Information

From the Cardiovascular Health Research Unit, Departments of Medicine, Epidemiology, and Health Services, University of Washington, Seattle (B.M.P.); and the Department of Public Health Sciences, Wake Forest University School of Medicine, Winston-Salem, N.C. (C.D.F.).

This article was published at www.nejm.org on February 15, 2005.

Related Letters:

Cardiovascular Risk Associated with Celecoxib
Brophy J. M., Solomon S. D., Wittes J., McMurray J., the APC Study Cardiovascular Safety Committee and Investigators , Psaty B. M., Furberg C. D.
Extract | Full Text | PDF  
N Engl J Med 2005; 352:2648-2650, Jun 23, 2005. Correspondence

This article has been cited by other articles:

• Stebbing, J., Powles, T., Mandalia, S., Nelson, M., Gazzard, B., Bower, M. (2008). Use of Antidepressants and Risk of Cancer in Individuals Infected With HIV. JCO 26: 2305-2310 [Abstract] [Full Text]  
• Darpo, B. (2007). Detection and reporting of drug-induced proarrhythmias: room for improvement. Europace 9: iv23-iv36 [Abstract] [Full Text]  
• Terre, L. (2007). Behavioral Medicine Review: The Dialectic of Tradition and Progress in Osteoarthritis Management. AMERICAN JOURNAL OF LIFESTYLE MEDICINE 1: 267-270 [Abstract]  
• Djavani, M. M., Crasta, O. R., Zapata, J. C., Fei, Z., Folkerts, O., Sobral, B., Swindells, M., Bryant, J., Davis, H., Pauza, C. D., Lukashevich, I. S., Hammamieh, R., Jett, M., Salvato, M. S. (2007). Early Blood Profiles of Virus Infection in a Monkey Model for Lassa Fever. J. Virol. 81: 7960-7973 [Abstract] [Full Text]  
• Borer, J. S., Pouleur, H., Abadie, E., Follath, F., Wittes, J., Pfeffer, M. A., Pitt, B., Zannad, F. (2007). Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval. Eur Heart J 28: 1904-1909 [Abstract] [Full Text]  
• Psaty, B. M., Furberg, C. D. (2007). Rosiglitazone and Cardiovascular Risk. NEJM 356: 2522-2524 [Full Text]  
• Salinas, G., Rangasetty, U. C., Uretsky, B. F., Birnbaum, Y. (2007). The Cycloxygenase 2 (COX-2) Story: It's Time to Explain, Not Inflame. J CARDIOVASC PHARMACOL THER 12: 98-111 [Abstract]  
• Bennett, C. L., Nebeker, J. R., Yarnold, P. R., Tigue, C. C., Dorr, D. A., McKoy, J. M., Edwards, B. J., Hurdle, J. F., West, D. P., Lau, D. T., Angelotta, C., Weitzman, S. A., Belknap, S. M., Djulbegovic, B., Tallman, M. S., Kuzel, T. M., Benson, A. B., Evens, A., Trifilio, S. M., Courtney, D. M., Raisch, D. W. (2007). Evaluation of Serious Adverse Drug Reactions: A Proactive Pharmacovigilance Program (RADAR) vs Safety Activities Conducted by the Food and Drug Administration and Pharmaceutical Manufacturers. Arch Intern Med 167: 1041-1049 [Abstract] [Full Text]  
• Psaty, B. M., Charo, R. A. (2007). FDA Responds to Institute of Medicine Drug Safety Recommendations--In Part. JAMA 297: 1917-1920 [Full Text]  
• Hall, R., de Antueno, C., Webber, A. (2007). Publication bias in the medical literature: a review by a Canadian Research Ethics Board: [Biais de publication dans la litterature medicale : un compte rendu d'un Comite d'ethique de recherche canadien]. Canadian J. Anesthesia 54: 380-388 [Abstract] [Full Text]  
• Kesten, S., Jara, M., Wentworth, C., Lanes, S. (2006). Pooled Clinical Trial Analysis of Tiotropium Safety. Chest 130: 1695-1703 [Abstract] [Full Text]  
• Aberegg, S. K., Arkes, H., Terry, P. B. (2006). Failure to Adopt Beneficial Therapies Caused by Bias in Medical Evidence Evaluation.. Med Decis Making 26: 575-582 [Abstract]  
• Harris, C. L, Raisch, D. W, Abhyankar, U., Marfatia, S., Campbell, H. M, Sather, M. R (2006). GI Risk Factors and Use of GI Protective Agents Among Patients Receiving Nonsteroidal Antiinflammatory Drugs. The Annals of Pharmacotherapy 40: 1924-1931 [Abstract] [Full Text]  
• Graham, D. J. (2006). COX-2 Inhibitors, Other NSAIDs, and Cardiovascular Risk: The Seduction of Common Sense. JAMA 296: 1653-1656 [Full Text]  
• Zhang, J., Ding, E. L., Song, Y. (2006). Adverse Effects of Cyclooxygenase 2 Inhibitors on Renal and Arrhythmia Events: Meta-analysis of Randomized Trials. JAMA 296: 1619-1632 [Abstract] [Full Text]  
• Stafford-Smith, M. (2006). Hurry up and slow down: Lessons in drug development from the COX-2 inhibitors/Se hater et ralentir: les lecons a tirer de la production des inhibiteurs de la COX-2.. Canadian J. Anesthesia 53: 973-977 [Full Text]  
• Fransen, M., Anderson, C., Douglas, J., MacMahon, S., Neal, B., Norton, R., Woodward, M., Cameron, I. D, Crawford, R., Lo, S. K., Tregonning, G., Windolf, M., HIPAID Collaborative Group, (2006). Safety and efficacy of routine postoperative ibuprofen for pain and disability related to ectopic bone formation after hip replacement surgery (HIPAID): randomised controlled trial. BMJ 333: 519- [Abstract] [Full Text]  
• Dvir, E., Friedman, J. E., Lee, J. Y., Koh, J. Y., Younis, F., Raz, S., Shapiro, I., Hoffman, A., Dahan, A., Rosenberg, G., Angel, I., Kozak, A., Duvdevani, R. (2006). A Novel Phospholipid Derivative of Indomethacin, DP-155 [Mixture of 1-Steroyl and 1-Palmitoyl-2-{6-[1-(p-chlorobenzoyl)-5-methoxy-2-methyl-3-indolyl acetamido]hexanoyl}-sn-glycero-3-phosophatidyl Choline], Shows Superior Safety and Similar Efficacy in Reducing Brain Amyloid beta in an Alzheimer's Disease Model. J. Pharmacol. Exp. Ther. 318: 1248-1256 [Abstract] [Full Text]  
• Psaty, B. M., Potter, J. D. (2006). Risks and benefits of celecoxib to prevent recurrent adenomas.. NEJM 355: 950-952 [Full Text]  
• Aritake, K., Kado, Y., Inoue, T., Miyano, M., Urade, Y. (2006). Structural and Functional Characterization of HQL-79, an Orally Selective Inhibitor of Human Hematopoietic Prostaglandin D Synthase. J. Biol. Chem. 281: 15277-15286 [Abstract] [Full Text]  
• Hur, C., Chan, A. T, Tramontano, A. C, Gazelle, G S. (2006). Coxibs Versus Combination NSAID and PPI Therapy for Chronic Pain: An Exploration of the Risks, Benefits, and Costs. The Annals of Pharmacotherapy 40: 1052-1063 [Abstract] [Full Text]  
• Askling, J, Fored, C M, Geborek, P, Jacobsson, L T H, van Vollenhoven, R, Feltelius, N, Lindblad, S, Klareskog, L (2006). Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 65: 707-712 [Abstract] [Full Text]  
• Huber, M. A., Terezhalmy, G. T. (2006). The use of COX-2 inhibitors for acute dental pain: A second look. Journal of the American Dental Association 137: 480-487 [Abstract] [Full Text]  
• Sooriakumaran, P (2006). COX-2 inhibitors and the heart: are all coxibs the same?. Postgrad. Med. J. 82: 242-245 [Abstract] [Full Text]  
• Chan, A. T., Manson, J. E., Albert, C. M., Chae, C. U., Rexrode, K. M., Curhan, G. C., Rimm, E. B., Willett, W. C., Fuchs, C. S. (2006). Nonsteroidal Antiinflammatory Drugs, Acetaminophen, and the Risk of Cardiovascular Events. Circulation 113: 1578-1587 [Abstract] [Full Text]  
• Caldwell, B., Aldington, S., Weatherall, M., Shirtcliffe, P., Beasley, R. (2006). Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis.. JRSM 99: 132-140 [Abstract] [Full Text]  
• Hull, M.A., Faluyi, O.O., Ko, C.W.S., Holwell, S., Scott, D.J., Cuthbert, R.J., Poulsom, R., Goodlad, R., Bonifer, C., Markham, A.F., Coletta, P.L. (2006). Regulation of stromal cell cyclooxygenase-2 in the ApcMin/+ mouse model of intestinal tumorigenesis. Carcinogenesis 27: 382-391 [Abstract] [Full Text]  
• Tyson-Capper, A. J., Europe-Finner, G. N. (2006). Novel Targeting of Cyclooxygenase-2 (COX-2) Pre-mRNA Using Antisense Morpholino Oligonucleotides Directed to the 3' Acceptor and 5' Donor Splice Sites of Exon 4: Suppression of COX-2 Activity in Human Amnion-Derived WISH and Myometrial Cells. Mol. Pharmacol. 69: 796-804 [Abstract] [Full Text]  
• Paul, M., Yahav, D., Fraser, A., Leibovici, L. (2006). Empirical antibiotic monotherapy for febrile neutropenia: systematic review and meta-analysis of randomized controlled trials. J Antimicrob Chemother 57: 176-189 [Abstract] [Full Text]  
• Ray, W. A., Stein, C. M. (2006). Reform of Drug Regulation -- Beyond an Independent Drug-Safety Board. NEJM 354: 194-201 [Full Text]  
• Ray, W. A. (2005). Observational studies of drugs and mortality.. NEJM 353: 2319-2321 [Full Text]  
• Deyle, G. D, Allison, S. C, Matekel, R. L, Ryder, M. G, Stang, J. M, Gohdes, D. D, Hutton, J. P, Henderson, N. E, Garber, M. B (2005). Physical Therapy Treatment Effectiveness for Osteoarthritis of the Knee: A Randomized Comparison of Supervised Clinical Exercise and Manual Therapy Procedures Versus a Home Exercise Program. ptjournal 85: 1301-1317 [Abstract] [Full Text]  
• Stebbing, J., Waters, L., Davies, L., Mandalia, S., Nelson, M., Gazzard, B., Bower, M. (2005). Incidence of Cancer in Individuals Receiving Chronic Zopiclone or Eszopiclone Requires Prospective Study. JCO 23: 8134-8136 [Full Text]  
• Rabins, P. V., Lyketsos, C. G. (2005). Antipsychotic Drugs in Dementia: What Should Be Made of the Risks?. JAMA 294: 1963-1965 [Full Text]  
• Caporali, R, Montecucco, C (2005). Cardiovascular effects of coxibs. Lupus 14: 785-788 [Abstract]  
• Konstantinopoulos, P. A., Lehmann, D. F. (2005). The Cardiovascular Toxicity of Selective and Nonselective Cyclooxygenase Inhibitors: Comparisons, Contrasts, and Aspirin Confounding. J Clin Pharmacol 45: 742-750 [Abstract] [Full Text]  
• Brophy, J. M., Solomon, S. D., Wittes, J., McMurray, J., the APC Study Cardiovascular Safety Committee and, , Psaty, B. M., Furberg, C. D. (2005). Cardiovascular Risk Associated with Celecoxib. NEJM 352: 2648-2650 [Full Text]  
• Bennett, C. L., Nebeker, J. R., Lyons, E. A., Samore, M. H., Feldman, M. D., McKoy, J. M., Carson, K. R., Belknap, S. M., Trifilio, S. M., Schumock, G. T., Yarnold, P. R., Davidson, C. J., Evens, A. M., Kuzel, T. M., Parada, J. P., Cournoyer, D., West, D. P., Sartor, O., Tallman, M. S., Raisch, D. W. (2005). The Research on Adverse Drug Events and Reports (RADAR) Project. JAMA 293: 2131-2140 [Abstract] [Full Text]  
• Tondini, C., Labianca, R. (2005). Tailoring a tailored treatment: the importance of fine-tuning on the patient. Ann Oncol 16: 683-685 [Full Text]